vs
ASP Isotopes Inc.（ASPI）与Immunovant, Inc.（IMVT）财务数据对比。点击上方公司名可切换其他公司
ASP Isotopes Inc.的季度营收约是Immunovant, Inc.的2.0倍（$16.7M vs $8.4M），ASP Isotopes Inc.同比增速更快（1295.7% vs 140.7%），ASP Isotopes Inc.自由现金流更多（$-47.4M vs $-59.8M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Immunovant是一家临床阶段生物制药企业，专注于开发用于治疗严重、罕见自身免疫性疾病及炎症性疾病的新型单克隆抗体疗法，其核心在研候选产品覆盖多种自身免疫适应症，面向全球医疗市场布局研发管线。
ASPI vs IMVT — 直观对比
营收规模更大
ASPI
是对方的2.0倍
$8.4M
营收增速更快
ASPI
高出1154.9%
140.7%
自由现金流更多
ASPI
多$12.4M
$-59.8M
损益表 — Q4 FY2025 vs Q4 FY2024
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $8.4M |
| 净利润 | — | $-75.3M |
| 毛利率 | 12.5% | — |
| 营业利润率 | — | -896.2% |
| 净利率 | — | -899.0% |
| 营收同比 | 1295.7% | 140.7% |
| 净利润同比 | -586.8% | -26.7% |
| 每股收益（稀释后） | — | $-0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPIIMVT
| Q4 25 | $16.7M | — | ||
| Q3 25 | $4.9M | — | ||
| Q1 24 | — | $8.4M | ||
| Q4 23 | — | $8.9M | ||
| Q3 23 | — | $3.6M | ||
| Q2 23 | — | $4.1M | ||
| Q1 23 | — | $3.5M | ||
| Q4 22 | — | $2.9M |
净利润ASPIIMVT
| Q4 25 | — | — | ||
| Q3 25 | $-12.9M | — | ||
| Q1 24 | — | $-75.3M | ||
| Q4 23 | — | $-51.4M | ||
| Q3 23 | — | $-58.7M | ||
| Q2 23 | — | $-73.9M | ||
| Q1 23 | — | $-59.4M | ||
| Q4 22 | — | $-63.2M |
毛利率ASPIIMVT
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
营业利润率ASPIIMVT
| Q4 25 | — | — | ||
| Q3 25 | -306.1% | — | ||
| Q1 24 | — | -896.2% | ||
| Q4 23 | — | -576.8% | ||
| Q3 23 | — | -1629.6% | ||
| Q2 23 | — | -1819.1% | ||
| Q1 23 | — | -1736.3% | ||
| Q4 22 | — | -2134.5% |
净利率ASPIIMVT
| Q4 25 | — | — | ||
| Q3 25 | -263.7% | — | ||
| Q1 24 | — | -899.0% | ||
| Q4 23 | — | -575.6% | ||
| Q3 23 | — | -1642.3% | ||
| Q2 23 | — | -1818.9% | ||
| Q1 23 | — | -1707.8% | ||
| Q4 22 | — | -2147.7% |
每股收益（稀释后）ASPIIMVT
| Q4 25 | — | — | ||
| Q3 25 | $-0.15 | — | ||
| Q1 24 | — | $-0.50 | ||
| Q4 23 | — | $-0.36 | ||
| Q3 23 | — | $-0.45 | ||
| Q2 23 | — | $-0.57 | ||
| Q1 23 | — | $-0.46 | ||
| Q4 22 | — | $-0.49 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $635.4M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $617.8M |
| 总资产 | $498.0M | $666.4M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPIIMVT
| Q4 25 | $333.3M | — | ||
| Q3 25 | $113.9M | — | ||
| Q1 24 | — | $635.4M | ||
| Q4 23 | — | $690.9M | ||
| Q3 23 | — | $269.9M | ||
| Q2 23 | — | $330.0M | ||
| Q1 23 | — | $376.5M | ||
| Q4 22 | — | $432.6M |
总债务ASPIIMVT
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
股东权益ASPIIMVT
| Q4 25 | $204.2M | — | ||
| Q3 25 | $74.1M | — | ||
| Q1 24 | — | $617.8M | ||
| Q4 23 | — | $679.3M | ||
| Q3 23 | — | $251.8M | ||
| Q2 23 | — | $299.9M | ||
| Q1 23 | — | $362.5M | ||
| Q4 22 | — | $414.7M |
总资产ASPIIMVT
| Q4 25 | $498.0M | — | ||
| Q3 25 | $225.9M | — | ||
| Q1 24 | — | $666.4M | ||
| Q4 23 | — | $711.4M | ||
| Q3 23 | — | $292.1M | ||
| Q2 23 | — | $351.2M | ||
| Q1 23 | — | $405.8M | ||
| Q4 22 | — | $456.2M |
负债/权益比ASPIIMVT
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-59.7M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $-59.8M |
| 自由现金流率自由现金流/营收 | -284.7% | -714.4% |
| 资本支出强度资本支出/营收 | 57.9% | 1.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-214.6M |
8季度趋势，按日历期对齐
经营现金流ASPIIMVT
| Q4 25 | $-37.8M | — | ||
| Q3 25 | $-8.9M | — | ||
| Q1 24 | — | $-59.7M | ||
| Q4 23 | — | $-47.1M | ||
| Q3 23 | — | $-60.1M | ||
| Q2 23 | — | $-47.4M | ||
| Q1 23 | — | $-55.8M | ||
| Q4 22 | — | $-46.4M |
自由现金流ASPIIMVT
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q1 24 | — | $-59.8M | ||
| Q4 23 | — | $-47.2M | ||
| Q3 23 | — | $-60.1M | ||
| Q2 23 | — | $-47.4M | ||
| Q1 23 | — | $-55.8M | ||
| Q4 22 | — | $-46.5M |
自由现金流率ASPIIMVT
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q1 24 | — | -714.4% | ||
| Q4 23 | — | -528.7% | ||
| Q3 23 | — | -1682.4% | ||
| Q2 23 | — | -1166.4% | ||
| Q1 23 | — | -1604.0% | ||
| Q4 22 | — | -1579.2% |
资本支出强度ASPIIMVT
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q1 24 | — | 1.8% | ||
| Q4 23 | — | 1.5% | ||
| Q3 23 | — | 1.0% | ||
| Q2 23 | — | 1.1% | ||
| Q1 23 | — | 0.7% | ||
| Q4 22 | — | 3.3% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
